Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

Publisher Name :
Date: 07-Aug-2018
No. of pages: 75

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

Summary

According to the recently published report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018'; Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) pipeline Target constitutes close to 21 molecules.

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Retinoic acid receptor gamma (RARG) is a nuclear receptor that is encoded by the RARG gene. RARG bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and regulate gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as an activator of gene expression due to weak binding to co-repressors. It is required for limb bud development.

The report 'Retinoic Acid Receptor Gamma - Pipeline Review, H2 2018' outlays comprehensive information on the Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 5, 6, 7 and 1 respectively.

Report covers products from therapy areas Dermatology, Musculoskeletal Disorders, Immunology, Oncology, Ophthalmology, Respiratory, Gastrointestinal and Genetic Disorders which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Allergies, Autoimmune Disorders, Congenital Ichthyosis, Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), Fibrosis, Gorlin Syndrome (Basal Cell Nevus Syndrome/ Nevoid Basal Cell Carcinoma Syndrome), Head And Neck Cancer, Inflammatory Bowel Disease, Keratoconjunctivitis Sicca (Dry Eye), Multiple Hereditary Exostoses, Plaque Psoriasis (Psoriasis Vulgaris) and Retinopathy Of Prematurity.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

- The report reviews Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics and enlists all their major and minor projects

- The report assesses Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Overview
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Companies Involved in Therapeutics Development
3SBio Inc
Bausch Health Companies Inc
Boehringer Ingelheim GmbH
Clementia Pharmaceuticals Inc
Galderma SA
Lee's Pharmaceutical Holdings Ltd
Phosphagenics Ltd
Promius Pharma LLC
Sol-Gel Technologies Ltd
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Drug Profiles
(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(adapalene + clindamycin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clindamycin phosphate + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(halobetasol propionate + tazarotene) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
bexarotene + CD1530 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palovarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize ROR-Gamma for Autoimmune and Allergic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules 1 to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize RARG for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize Retinoic Acid Receptor Gamma for Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trifarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Dormant Products
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Discontinued Products
Retinoic Acid Receptor Gamma (RAR Gamma or Nuclear Receptor Subfamily 1 Group B Member 3 or NR1B3 or RARG) - Product Development Milestones
Featured News & Press Releases
Jun 18, 2018: FDA declines to approve Valeant's plaque psoriasis lotion
Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion
May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
Apr 20, 2018: Clementia Initiates Phase 2 MO-Ped Trial for Palovarotene in Patients with Multiple Osteochondromas
Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology
Feb 15, 2018: Sol-Gel's Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting
Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
Dec 12, 2017: Clementia Initiates Pivotal Phase 3 MOVE Trial for Palovarotene in Patients with Fibrodysplasia Ossificans Progressiva
Nov 20, 2017: Preclinical study demonstrates promising treatment for rare bone disease
Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris
Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
Sep 05, 2017: Ortho Dermatologics Submits New Drug Application To The U.S. Food And Drug Administration For Psoriasis Treatment IDP-118
Aug 31, 2017: Clementia Announces Data Presentations at Upcoming Medical Conferences in September
Jul 20, 2017: Sol-Gel Announces Positive Phase 2 Clinical Trial Results for TWIN in Patients with Acne Vulgaris
Jun 05, 2017: Clementia Pharmaceuticals to Host Symposium at the 8th International Conference on Children's Bone Health
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by 3SBio Inc, H2 2018
Pipeline by Bausch Health Companies Inc, H2 2018
Pipeline by Boehringer Ingelheim GmbH, H2 2018
Pipeline by Clementia Pharmaceuticals Inc, H2 2018
Pipeline by Galderma SA, H2 2018
Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2018
Pipeline by Phosphagenics Ltd, H2 2018
Pipeline by Promius Pharma LLC, H2 2018
Pipeline by Sol-Gel Technologies Ltd, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd..1), H2 2018
Discontinued Products, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • 2018-2023 Global Liquid Chromatography Detectors Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 131
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Liquid Chromatography Detectors market for 2018-2023. Liquid Chromatography Detectors is a device used in liquid chromatography (LC) to detect components of the mixture being eluted off the chromatography column. A broad range of detectors is available to meet different sample requirements. Specific detectors respond to a particular compound only and the re......
  • 2018-2023 Global Platelet Rich Plasma (PRP) Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Platelet Rich Plasma (PRP) market for 2018-2023. Platelet Rich Plasma is a biologic isolated from whole blood that is preferentially enriched for platelets. While platelets are the primary component of PRP, preparations may also contain other cellular components such as white blood cells (WBCs) and peripheral stem cells. These components all play a biologic......
  • 2018-2023 Global Pimozide Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Pimozide market for 2018-2023. Pimozide (sold under the brand name Orap) is an antipsychotic drug of the diphenylbutylpiperidine class. It was discovered at Janssen Pharmaceutica in 1963. It has a high potency compared to chlorpromazine (ratio 50-70:1). On a weight basis it is even more potent than haloperidol. It also has special neurologic indications for......
  • 2018-2023 Global Vitamin B12 (Cobalamin, Cyanocobalamin) Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 162
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Vitamin B12 (Cobalamin, Cyanocobalamin) market for 2018-2023. This report studies the Cyanocobalamin market, Cyanocobalamin is a man-made form of vitamin B12. Vitamin B12 is important for growth, cell reproduction, blood formation, and protein and tissue synthesis. Cyanocobalamin is used to treat vitamin B12 deficiency in people with pernicio......
  • 2018-2023 Global Enteral Feeding Tube Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 158
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Enteral Feeding Tube market for 2018-2023. Enteral feeding refers to the delivery of a nutritionally complete feed, containing protein, carbohydrate, fat, water, minerals and vitamins, directly into the stomach, duodenum or jejunum. A feeding tube is a medical device used to provide nutrition to people who cannot obtain nutrition by mouth, ar......
  • 2018-2023 Global Medicinal Mushroom Extracts Consumption Market Report
    Published: 20-Aug-2018        Price: US 4660 Onwards        Pages: 162
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Medicinal Mushroom Extracts market for 2018-2023. Medicinal mushrooms have long been recognized for their health benefits in Eastern medicine; traditional medicine has used mushrooms for thousands of years. Studies have found that these medicinal mushrooms contain a variety of components that act as antioxidants, support immune function, and even promote ce......
  • Global and India Plasminogen Market Research by Company, Type & Application 2013-2025
    Published: 19-Aug-2018        Price: US 2000 Onwards        Pages: 81
    Summary Plasminogen, the proenzyme of the fibrinolytically active enzyme plasmin, is a single chain glycoprotein with a molecular weight of about 90,000-94,000 Da (2). Various isoelectric forms exist and can be separated by means of isoelectric focusing (IEF). Market Segment as follows: By Type - Intravenous Injection - Eye drops By Application - Ligneous Conjunctivitis - Diabetic Foot - Wound Healing ......
  • Global and India Vegetable (HPMC) Capsule Market Research by Company, Type & Application 2013-2025
    Published: 19-Aug-2018        Price: US 2000 Onwards        Pages: 103
    Summary Hydroxypropyl methylcellulose is a methylcellulose modified with a small amount of propylene glycol ether groups attached to the anhydroglucose of the cellulose. HPMC Capsules are two-piece capsules made from cellulosic raw materials that satisfy vegetarian, religion, cultural and policy needs. These vegetable capsules are an attractive, all natural dosage form that retain all the advantages - easy to swallow, effectively mask taste and odor, and allow product visibility. ......
  • Global and India Prostaglandin Market Research by Company, Type & Application 2013-2025
    Published: 19-Aug-2018        Price: US 2000 Onwards        Pages: 116
    Summary Prostaglandins control several processes in the body, especially as it relates to the healing process. When tissue is damaged or infected, this group of hormones will create the reactions that cause pain, fever and inflammation, which sparks the healing process. Prostaglandins also stimulate the formation of a blood clot and the contraction of the blood vessel wall when body is bleeding. Once blood clots are no longer needed and the injury begins to heal, another prostagla......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs